Literature DB >> 19289528

Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates.

Helio S Sader1, Thomas R Fritsche, Ronald N Jones.   

Abstract

The in vitro activity of iclaprim, a novel diaminopyrimidine derivative, was evaluated against 5,937 recent gram-positive clinical isolates collected in the United States and Europe. Iclaprim demonstrated potent activity against Staphylococcus aureus (including methicillin-resistant S. aureus [MRSA]), beta-hemolytic Streptococcus spp., and Enterococcus faecalis strains tested. In addition, iclaprim exhibited bactericidal activity against all S. aureus strains tested, including MRSA.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19289528      PMCID： PMC2681558          DOI： 10.1128/AAC.00129-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Identification of Harper-Cawston factor as thymidine phosphorylase and removal from media of substances interfering with susceptibility testing to sulfonamides and diaminopyrimidines.

Authors:  R Ferone; S R Bushby; J J Burchall; W D Moore; D Smith
Journal:  Antimicrob Agents Chemother       Date:  1975-01       Impact factor: 5.191

2.  Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene.

Authors:  Soju Chang; Dawn M Sievert; Jeffrey C Hageman; Matthew L Boulton; Fred C Tenover; Frances Pouch Downes; Sandip Shah; James T Rudrik; Guy R Pupp; William J Brown; Denise Cardo; Scott K Fridkin
Journal:  N Engl J Med       Date:  2003-04-03       Impact factor: 91.245

3.  Practice guidelines for the diagnosis and management of skin and soft-tissue infections.

Authors:  Dennis L Stevens; Alan L Bisno; Henry F Chambers; E Dale Everett; Patchen Dellinger; Ellie J C Goldstein; Sherwood L Gorbach; Jan V Hirschmann; Edward L Kaplan; Jose G Montoya; James C Wade
Journal:  Clin Infect Dis       Date:  2005-10-14       Impact factor: 9.079

Review 4.  Treatment challenges in the management of complicated skin and soft-tissue infections.

Authors:  B I Eisenstein
Journal:  Clin Microbiol Infect       Date:  2008-03       Impact factor: 8.067

5.  Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  A Mangili; I Bica; D R Snydman; D H Hamer
Journal:  Clin Infect Dis       Date:  2005-02-17       Impact factor: 9.079

Review 6.  Iclaprim.

Authors:  Stephan A Kohlhoff; Roopali Sharma
Journal:  Expert Opin Investig Drugs       Date:  2007-09       Impact factor: 6.206

Review 7.  Newer treatment options for skin and soft tissue infections.

Authors:  Murugan Raghavan; Peter K Linden
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.

Authors:  Gregory Steinkraus; Roger White; Lawrence Friedrich
Journal:  J Antimicrob Chemother       Date:  2007-07-10       Impact factor: 5.790

9.  Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections.

Authors:  William J Peppard; Christopher D Schuenke
Journal:  Curr Opin Investig Drugs       Date:  2008-02

10.  Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria.

Authors:  Peter Schneider; Stephen Hawser; Khalid Islam
Journal:  Bioorg Med Chem Lett       Date:  2003-12-01       Impact factor: 2.823
View more
  10 in total

Review 1.  Diabetic foot infections: microbiological aspects, current and future antibiotic therapy focusing on methicillin-resistant Staphylococcus aureus.

Authors:  Andreas Ambrosch; Simone Haefner; Edward Jude; Ralf Lobmann
Journal:  Int Wound J       Date:  2011-08-23       Impact factor: 3.315

2.  Pharmacokinetic and Pharmacodynamic Analyses To Determine the Optimal Fixed Dosing Regimen of Iclaprim for Treatment of Patients with Serious Infections Caused by Gram-Positive Pathogens.

Authors:  Thomas P Lodise; John Bosso; Colleen Kelly; Paul J Williams; James R Lane; David B Huang
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

3.  Efficacy evaluation of iclaprim in a neutropenic rat lung infection model with methicillin-resistant Staphylococcus aureus entrapped in alginate microspheres.

Authors:  David B Huang; Ian Morrissey; Timothy Murphy; Stephen Hawser; Mark H Wilcox
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-12-08       Impact factor: 3.267

4.  A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study).

Authors:  Thomas L Holland; William O'Riordan; Alison McManus; Elliot Shin; Ali Borghei; Thomas M File; Mark H Wilcox; Antoni Torres; Matthew Dryden; Thomas Lodise; Toyoko Oguri; G Ralph Corey; Patrick McLeroth; Rajesh Shukla; David B Huang
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

5.  Multicenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections.

Authors:  D Krievins; R Brandt; S Hawser; P Hadvary; K Islam
Journal:  Antimicrob Agents Chemother       Date:  2009-05-04       Impact factor: 5.191

6.  In Vitro Activity of Iclaprim against Methicillin-Resistant Staphylococcus aureus Nonsusceptible to Daptomycin, Linezolid, or Vancomycin: A Pilot Study.

Authors:  David B Huang; Stephen Hawser; Curtis G Gemmell; Daniel F Sahm
Journal:  Can J Infect Dis Med Microbiol       Date:  2017-12-17       Impact factor: 2.471

Review 7.  An Updated Review of Iclaprim: A Potent and Rapidly Bactericidal Antibiotic for the Treatment of Skin and Skin Structure Infections and Nosocomial Pneumonia Caused by Gram-Positive Including Multidrug-Resistant Bacteria.

Authors:  David B Huang; Catherine D Strader; James S MacDonald; Mark VanArendonk; Richard Peck; Thomas Holland
Journal:  Open Forum Infect Dis       Date:  2018-01-06       Impact factor: 3.835

Review 8.  Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms.

Authors:  Despoina Koulenti; Elena Xu; Andrew Song; Isaac Yin Sum Mok; Drosos E Karageorgopoulos; Apostolos Armaganidis; Sotirios Tsiodras; Jeffrey Lipman
Journal:  Microorganisms       Date:  2020-01-30

9.  Efficacy and Safety of Iclaprim for the Treatment of Skin Structures and Soft Tissue Infections: A Methodological Framework.

Authors:  Lian Wang; Jin Fan; Linli Zheng; Lingmin Chen
Journal:  Front Pharmacol       Date:  2022-07-19       Impact factor: 5.988

10.  Evaluation of the Bactericidal Activity of Plazomicin and Comparators against Multidrug-Resistant Enterobacteriaceae.

Authors:  M Thwaites; D Hall; D Shinabarger; A W Serio; K M Krause; A Marra; C Pillar
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.